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Anthrax infections are frequently associated with severe and often irreversible hypotensive shock. The isolated toxic proteins
of Bacillus anthracis produce a non-cytokine-mediated hypotension in rats by unknown mechanisms. These observations
suggest the anthrax toxins have direct cardiovascular effects. Here, we characterize these effects. As a first step, we
administered systemically anthrax lethal toxin (LeTx) and edema toxin (EdTx) to cohorts of three to twelve rats at different
doses and determined the time of onset, degree of hypotension and mortality. We measured serum concentrations of the
protective antigen (PA) toxin component at various time points after infusion. Peak serum levels of PA were in the mg/mL range
with half-lives of 10–20 minutes. With doses that produced hypotension with delayed lethality, we then gave bolus
intravenous infusions of toxins to groups of four to six instrumented rats and continuously monitored blood pressure by
telemetry. Finally, the same doses used in the telemetry experiments were given to additional groups of four rats, and
echocardiography was performed pretreatment and one, two, three and twenty-four hours post-treatment. LeTx and EdTx
each produced hypotension. We observed a doubling of the velocity of propagation and 20% increases in left ventricular
diastolic and systolic areas in LeTx-treated rats, but not in EdTx-treated rats. EdTx-but not LeTx-treated rats showed
a significant increase in heart rate. These results indicate that LeTx reduced left ventricular systolic function and EdTx reduced
preload. Uptake of toxins occurs readily into tissues with biological effects occurring within minutes to hours of serum toxin
concentrations in the mg/mL range. LeTx and EdTx yield an irreversible shock with subsequent death. These findings should
provide a basis for the rational design of drug interventions to reduce the dismal prognosis of systemic anthrax infections.
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INTRODUCTION
Bacillus anthracis is a spore-forming, Gram-positive bacterium and is
the causative agent of anthrax. Infection by inhalation of B. anthracis
spores can result in a mortality rate of up to 80% [1]. Despite a long
history of Bacillus anthracis infections as a cause of human and animal
disease and its notoriety as an agent of biological warfare, exactly
how the bacteria kill the host is unclear. Although aggressive
antibiotic therapy can prevent bacterial growth, infected individuals
still die, most probably due to high concentrations of anthrax toxins
already accumulated in the body [2].
Bacillus anthracis vegetative bacteria secrete three proteins—
protective antigen (PA), lethal factor (LF), and edema factor (EF)
which combine to form anthrax lethal toxin (LeTx; PA and LF)
and anthrax edema toxin (EdTx; PA and EF) [3]. PA binds
receptors tumor endothelial marker 8 (TEM8) and capillary
morgenesis gene-2 (CMG2) on normal tissues, undergoes cell
surface furin-mediated endoproteolytic cleavage and release of
a twenty kilodalton fragment, oligomerization of the remaining
sixty-three kilodalton PA portions to form heptamers, followed by
binding of three molecules of LF or EF per heptamer [4]. The
toxin-receptor complex is depalmitoylated, associates with co-
receptors including low-density lipoprotein receptor-related pro-
tein 6 (LRP6), migrates into lipid rafts, is E3 ubiquitin ligase Cbl-
ubiquinated, associates with Eps15 and then undergoes clathrin-
mediated endocytosis [5]. After acidification in endosomes, the PA
2b2-2b3 strands unfold, insert into the endosomal membranes,
dissociate from the CMG2 and TEM8 receptors, and create a 14-
member b-barrel pore [6]. EF and LF bind to the pore entrance
and translocate to the cytosol with a cytosolic translocation factor
chaperone [7]. In the cytosol, LF is a Zn2+-metalloprotease which
specifically cleaves the NH2-termini of mitogen-activated protein
kinase kinases (MEKs) resulting in their inactivation [8].
Intoxicated cells lose normal mitogen-activated kinase pathway
signaling. EF is a calmodulin-dependent adenylyl cyclase that
elevates intracellular levels of cAMP and produces altered cell
physiology [9]. Evidence for the central role of the toxins in
anthrax pathogenesis includes the lethality of purified preparations
of LeTx and EdTx in rodents [10,11], the thousand-fold reduction
in toxicity of bacterial strains with mutated, inactivated anthrax
toxin genes [12] and the protection of animals from death due to
Bacillus anthracis infection by prophylactic treatment with anti-
bodies or vaccines to anthrax toxins [13,14].
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In the 2001 bioterrorism anthrax experience, patients with
inhalational anthrax developed refratory hypotension [15,16]. In
part due to the acuteness and severity of the events, full
hemodynamic and molecular studies were not conducted. In
contrast to lipopolysaccharide-induced endotoxic shock, excessive
inflammatory cytokine and nitric oxide release do not appear to
contribute to the circulatory shock and lethality occurring with
anthrax toxins in rodent models [10,11,17,18]. These results imply
a possible complex pathophysiology for anthrax associated shock.
The purpose of this study was to determine the acute cardiac and
vascular hemodynamic effects of LeTx and EdTx in the rat and
demonstrate that many of abnormalities are consistent with
human inhalation anthrax pathophysiology.
Newer methods used in this study to dissect the pathophysiology
of shock in unrestrained rodents include instrumentation with
intra-aortic catheter probes connected to telemetry units and
transthoracic echocardiography with state-of-the-art ultrasound
technology. These methods permit dissection of the contribution
of the heart, blood volume and blood vessels to cardiac output and
blood pressure.
RESULTS
Effects of LeTx and EdTx Dosage on Mortality
Examination of toxicity in Sprague Dawley rats was performed by
an intravenous injection of different doses of LeTx and EdTx and
mortality (Table 1). Survival curves for rats treated with single
intravenous bolus infusion of LeTx (0.03 mg PA+0.015 mg LF) or
EdTx (0.15 mg PA+0.075 mg EF) is shown in Figure 1. All of the
LeTx deaths occurred within the first 6 hr, whereas the last EdTx
death occurred after 72 hr. The Kaplan-Meier survival of LeTx-
treated rats, compared to control is not significantly different
(p=0.08 and Fisher’s exact p=0.11). Kaplan-Meier survival of
controls versus EdTx is statistically significant (p. value=0.047 and
Fisher’s exact p=0.038). We chose doses for further studies of LeTx
(0.03 mg PA+0.15 mg LF) and EdTx (0.15 mg PA and 0.075 mg
EF) which yielded 58% survival and 42% survival, respectively.
Serum Levels of Anthrax toxins
To determine half-life and plasma levels of PA following injection,
rats were administered various doses of LeTx (2:1 ratios of PA/LF)
and EdTx (2:1 ratios of PA/EF) via the tail-vein injection. The LeTx
was given as single bolus infusions using doses of 0.024 mg
PA+0.012 mg LF, 0.03 mg PA+0.015 mg LF, 0.032 mg
PA+0.016 mg LF, 0.04 mg PA+0.02 mg LF in 500 mL phosphate-
buffered saline (PBS). EdTx was given as single bolus infusions of
0.15 mg PA+0.075 mg EF in 500 mL PBS. After various times (0–
250 min) blood samples were collected and plasma levels of PA were
analyzed using ELISA, as described in the methods. As shown in
Table 2 and Figure 2, higher doses of anthrax toxin resulted in
increased serum concentrations of PA. Peak levels were in the mg/
mL range and half-lives were 10–20 minutes.
Blood Pressure Telemetry Measurements
Hemodynamic parameters were measured by telemetry of
conscious Sprague Dawley rats that were treated with single
intravenous bolus infusions of toxins. Radiofrequency measure-
ments of baseline heart rate and blood pressures were recorded for
Figure 1. Survival of Sprague Dawley rats (250 to 300 g) treated with
single intravenous bolus infusion of LeTx (0.03 mg PA+0.015 mg LF)
or EdTx (0.15 mg PA+0.075 mg EF) and monitored for two weeks.
These are the same doses used for telemetry and ECHO experiments.
N = 12 for each experiment. Kaplan-Meier graphs prepared.
doi:10.1371/journal.pone.0000466.g001
Table 1. Mortality of Anthrax Toxins*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Toxin Dose (PA/LF or EF) Mortality (%)
LeTx 0.04 mg/0.02 mg 100 (n = 3)
0.032 mg/0.016 mg 66 (n = 3)
0.03 mg/0.015 mg 42 (n = 12)
0.024 mg/0.012 mg 33 (n = 3)
EdTx 0.15 mg/0.075 mg 58 (n = 12)
0.075 mg/0.0375 mg 0 (n = 3)
0.04 mg/0.02 mg 0 (n = 3)
*n= the number of animals used in each dose study
doi:10.1371/journal.pone.0000466.t001..
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Table 2. Anthrax toxins in serum samples*
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Toxin Dose (PA/LF or EF) Half-life of PA (min) Co (mg/ml) of PA
LeTx 0.04 mg/0.02 mg 17 2.9
0.032 mg/0.016 mg 12 2.8
0.03 mg/0.015 mg 12 1.4
0.024 mg/0.012 mg 12 0.9
EdTx 0.15 mg/0.075 mg 23 11.4
*Three animals were used in each dose study; ND, not determined.
doi:10.1371/journal.pone.0000466.t002..
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Figure 2. Serum levels of PA after single bolus intravenous infusions
of different doses of LeTx to Sprague Dawley rats (250 to 300 g).
Concentrations of toxin components measured by ELISA as described in
the text. Peak concentrations and half-lives shown in Table 2.
doi:10.1371/journal.pone.0000466.g002
Anthrax Toxin CV Effects
PLoS ONE | www.plosone.org 2 May 2007 | Issue 5 | e466
72 hr, after which rats were administered tail-vein injections of
LeTx (0.03 mg PA+0.015 mg LF), EdTx (0.15 mg PA+0.075 mg
EF) or PBS (control). Bradycardia and hypotension developed in
rats within 1 hr after exposure to LeTx (Figure 3). The rapid onset
of bradycardia and decrease in systolic and diastolic pressure is
consistent with a primary effect of LeTx on the heart. Although
rats administered EdTx demonstrated decreases in systolic,
diastolic and mean arterial pressures after 18–48 hr, an increase
in heart rate occurred (Figure 3). The increase in heart rate may
represent compensation for the lowered blood pressure. There was
a widened pulse pressure and reduction in diastolic blood pressure
consistent with reduced systemic vascular resistance and reduced
vascular tone.
Effects of LeTx and EdTx on Cardiac Function
Echocardiographic parameters including velocity of propagation
(Vp), left ventricular diastolic area (LVAd), left ventricular systolic
area (LVAs), heart rate were monitored at different times post
anthrax toxin bolus iv infusion (Figure 4). LeTx treated rat hearts
showed significant changes at one and two hrs with increased Vp,
increased LVAd, and increased LVAs (Figure 4A, B, and C). Vp
was 2465, 3467 and 46617 cm/sec at 0, 1 and 2 hrs, respec-
tively, with significant difference (P= 0.05 at one hr compared to
controls and P= 0.007 at two hr compared to controls). LVAd was
0.9860.07 and 1.1560.06 at 0 and 1 hour, respectively, with
significant difference (P= 0.01). LVAs was 0.7960.08 and 0.986
0.10 cm at 0 and 1 hr, respectively, with significant difference
(P = 0.02). These changes indicate LeTx induced myocardial
effects. The Vp doubled by two hr and LVAd and LVAs increased
by 20% in one hr. These results suggest that increased left
ventricular end-systolic volume precedes the reduction in ejection
fraction.
EdTx treated rat hearts showed significant increases in heart
rate compared to controls at one and two hr post-injection
(Figure 4D). Heart rate was 326649, 371628, and 393610 beats
per min at 0, 1 and 2 hours, respectively, with significant
difference (P= 0.05 at one hr and P=0.001 at two hr compared
to controls). At one hour, rats treated with EdTx failed to show the
changes in velocity of propagation or ventricular areas observed
with LeTx (data not shown), consistent with a decrease in preload.
In addition, there were no significant differences between controls
and EdTx injected rats for ejection fraction, fractional shortening,
and corrected velocity of circumferential fiber shortening suggest-
ing EdTx has no direct myocardial effects. Taken together, the
EdTx-induced sinus tachycardia is an expected early response to
reduced preload.
DISCUSSION
The studies presented here provide the first detailed analyses of
cardiovascular toxicity induced by purified anthrax toxins in a rat
model. Both toxins induce significant hypotension. Importantly,
LeTx and EdTx appear to produce the hypotension by affecting
different parts of the cardiovascular system. Serum levels of toxins
were measurable in all tested rats. Lethality and hypotension were
associated with doses of toxins that produced peak PA levels in the
mg/mL range. This is consistent with the measurements of toxin
levels in spore-infected animals [2,19]. Hypotension and death
occurred within hr of reaching similar ranges of toxin in the blood
of infected rats, rabbits and guinea pigs.
LeTx rapidly induced acute myocardial dysfunction similar to
that observed with fulminant myocarditis with significant increases
in the LV systolic area, LV diastolic area, and ventricular
compliance. Left ventricular dilatation was expected from acute
Figure 3. Hemodynamic parameters measured by telemetry of
conscious Sprague Dawley rats (250g to 300g) treated with single
intravenous bolus infusions of LeTx (0.03 mg PA+0.015 mg LF) or
EdTx (0.15 mg PA+0.075 mg EF). A. Heart rate (beats per min), B. Pulse
pressure (mmHg), C. Mean arterial pressure (mmHg), D. Systolic blood
pressure (mmHg), and E. Diastolic blood pressure (mmHg) were
measured every 15 min. for 72 hr before and after toxin administration.
doi:10.1371/journal.pone.0000466.g003
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myocardial dysfunction such as fulminant myocarditis. Increased
ventricular compliance is implied by the increased Vp. Ogawa
reported that Vp was positively correlated with stroke volume,
heart rate and left ventricular compliance [20]. Since stroke
volume and heart rate did not significantly change, then increased
ventricular compliance is the likely explanation for increases in
Vp. Increased left ventricular compliance may be due to loss of
functional intercalated discs that connect the myocardial cells. In
contrast, EdTx has an intravascular volume effect. This observa-
tion is compatible with ‘‘third spacing’’ or decreased intravascular
volume due to rapid fluid shifts out of the blood vessels.
Both observations are consistent with published results of toxin-
induced rodent hypotension. Mice intravenously infused with
LeTx developed malaise and death by 60–100 hr [10,18,21].
Corticosteroids and aldosterone were unable to prevent lethality or
shock. Histopathology showed hypoxic tissue necrosis in liver,
marrow, spleen and heart, pleural and peritoneal fluid and edema.
There were elevations of serum erythropoietin and transaminase
and hypoalbuminemia, hypofibrinogenemia, thrombocytopenia,
elevated prothrombin time and partial thromboplastin time, and
disseminated fibrin deposition and hemorrhage. Rats treated with
LeTx died after two to twenty-one hr with refractory hypotension,
bradycardia, lactic acidosis, and pleural effusions [13,17,22,23].
Again, these results are consistent with shock and hypoxic
secondary tissue injury. Mice treated with EdTx died with one
to three days with hypotensive shock and ‘‘third spacing’’ in the
intestinal lumen and other tissues [11]. Pathology showed fluid
accumulation in intestines, adrenal hemorrhage, lymphocytolysis,
osteoblast necrosis, and elevated transaminases and urea nitrogen.
These results coincide with our observation of a reduction in
preload due to a loss of vascular volume and tone. Additional
studies in anthrax toxin-treated rats will be performed in our
laboratory to better investigate the cardiac and vascular anatomy.
Previous reports support a critical role for mitogen activated
protein kinase (MAPK) signaling in the heart. Tissue culture
studies with antisense molecules and knockout mice show
cardiomyocyte injury with impaired MEK1/2-ERK1/2 kinase
activities [24]. Cancer patients treated with a small molecular
weight MEK inhibitor develop heart failure [25]. Similarly,
increases in vascular endothelial cAMP from calcitonin gene-
related peptide G-protein activation led to decreased vascular
resistance in hepatic, coronary, skin and gastric vessels [26]. Thus,
the cAMP pathway is important in vascular homeostasis.
Additional studies with tissues from anthrax toxin treated animals
will be needed to confirm changes in these vital tissue-signaling
pathways.
The observed cardiovascular defects induced by anthrax toxins
were dependent on the presence of two toxin components (PA+LF
or PA+EF). Rats received IV infusion of LF alone survived and
showed no symptom of hypotension (data not shown). Previous
studies have demonstrated that, in the absence of PA, injection of
EF does not cause any symptom in treated animals [11,27]. In
addition, only combination of PA with LF or EF, but not LF or EF
alone, displays toxicity in macrophage cells [28] and suppresses T
lymphocyte activation [29].
Combinations of LeTx and EdTx as occurs in systemic anthrax
infections would be predicted to generate more severe and
irreversible hypotension due to an inability of either the heart or
blood vessels to respond to lesions in the other organ. Preliminary
studies with combinations of EdTx and LeTx show worse
hypotension and greater lethality [23]. Examination of the
hemodynamic parameters described in the current study with
rats treated with mixtures of LeTx and EdTx will be useful to
confirm these predictions.
Figure 4. Boxplots at different times post anthrax toxin bolus iv
infusion of echocardiographic parameters: A. LeTx treated rats at zero,
one and two hr post-infusion, velocity of propagation was 2465, 3467
and 46617 cm/sec, respectively, with significant difference (P = 0.05 at
one hr compared to controls and P= 0.007 at two hr compared to
controls); B. LeTx treated rats at zero and one hr post-infusion, left
ventricular diastolic area was 0.9860.07 and 1.1560.06, respectively,
with significant difference (P = 0.01); C. LeTx treated rats at zero and one
hr post-infusion, left ventricular systolic area was 0.7960.08 and
0.9860.10 cm, respectively, with significant difference (P = 0.02); D.
EdTx treated rats at zero, one and two hr post-infusion, heart rate was
326649, 371628, and 393610 beats per min, respectively, with
significant difference (P = 0.05 at one hr and P= 0.001 at two hr
compared to controls). The box represents the middle 50% of the data.
The line through the box represents the median. The line (whiskers)
extending from the box represent the upper and lower 25% of the data.
The line of each plot connects the means of the sample.
doi:10.1371/journal.pone.0000466.g004
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In summary, these results suggest that the pathophysiology of
anthrax shock may be closely linked with circulating toxins and
involve both a rapid reduction in left ventricular preload and
systolic function. Intervention to rescue animals and patients with
anthrax shock will need to address both of these cardiovascular
lesions. Rodents and other species provide an excellent system to
test new therapeutics for this devastating disease.
MATERIALS AND METHODS
Toxins
Anthrax toxin components PA, LF and EF were produced at over
95% purity with low endotoxin level as previously described [30–
32,28]. All toxin preparations were diluted in 1X phosphate-
buffered saline (PBS), filter-sterilized, frozen and thawed only once
prior to use. In each case, we used twice the amount of PA
compared to LF or EF.
Animals
Male Sprague-Dawley rats weighing between 180 and 230 g were
purchased from Charles River Laboratories (Cambridge, MA) and
allowed a one-week acclimation period after arrival to the animal
facilities at Scott and White before experimentation or surgical
procedures. Rat weights at the time of experiments were 250 to
300 g. Animals were housed two per polycarbonate tub with wood
shavings and allowed food (Purina Rat Chow) and tap water ad
libitum. The colony room lights were regulated on a 12:12-h light-
dark cycle. Care and use of animals were designed in accordance
with National Institutes of Health and American Association for
the Accreditation of Laboratory Animal Care (AAALAC) guide-
lines, and approved by the Scott and White Memorial Hospital/
Texas A and M University System Health Science Center
Institutional Animal Care and Use Committee. Rats received
bolus intravenous 500 mL infusions of sterile PBS, LeTx or EdTx.
Survival Curves
Groups of three to twelve animals received intravenous injections
of various doses of LeTx, EdTx, or toxin subcomponent. Animals
were monitored post-injection hourly for eight hours and then
every twelve hr for activity, posture, eating and drinking, and hair
condition. Moribund animals were euthanized. Kaplan-Meier
survival curves were compared by the log-rank test.
Measurement of Anthrax Toxin Pharmacokinetics
Clearance of PA from the circulation of Sprague Dawley rats was
determined following intravenous tail-vein injection of toxin into
three rats. Tail-vein blood samples (100–200 mL) were collected at
15, 20, 30, 90, 100, 168, 240 and 1440 min-post injection, after
which serum was harvested by sedimentation (14,000 rpm,
10 min, 22uC). Aliquots of serum were stored at280uC until
assayed. ELISA plates (Corning Costar 9018, Acton, MD) were
incubated (16 hr, 4uC) with capture anti-PA antibody (2 mg/mL of
14B7) [33]. After wells were washed (PBS plus 0.05% Tween-20)
and blocked (200 mL 5% non-fat milk) for one hour, 100 mL of
serum sample (in 1:20 and 1:100 dilution) or standard (0 to 1 mg/
mL of PA in 1:20 dilution of rat serum) in PBS containing 1%
bovine serum albumin was added and incubated for one hr at
room temperature. Plates were rewashed and reacted for two hr
with 100 mL of 1 mg/mL biotinylated detection anti-PA antibody
(8240, Abcam, Cambridge, MA). Biotinylation of anti-PA de-
tection antibodies was prepared following the recommendations of
the manufacturer (Pierce 21450 Kit, Pierce Biotechnology,
Rockford, IL). After washing, 100 ml of horseradish peroxidase-
conjugated streptavidin (1:8000, R&D Systems, Minneapolis, MN)
was added and incubated for 1 hr. Wells were washed and
incubated with 100 mL R&D substrate reagent 895000 for 20 min.
Color development was stopped with 100 mL 2N H2SO4 and
absorbance measured at 450 nm on a VERSAmax microplate
reader (Molecular Devices, Sunnyvale, CA). Each test was
performed in triplicate and the average of the data points was
plotted using GraphPad Prism 4 (GraphPad, San Diego, CA).
Curved-fits were calculated with one phase exponential decay
equation: Y=Span (e2kX)+Plateau, k is elimination rate constant.
The PA assay had a range of 3.91 ng/mL to 500 ng/mL with the
inter-assay and intra-assay coefficients of variation less than 15%.
Telemetry Measurements
Radio frequency devices were implanted for independent
monitoring of blood pressure or heart rate using devices from
Data Sciences Int. (St. Paul, MN) as described [34]. Briefly, rats
randomized into control (N= 4), LeTx (N= 6) and EdTx (N= 5)
groups were anesthetized with ketamine-xylazine, after which
transmitters were implanted in the peritoneal cavity and attached
pressure catheters were placed in the aortic lumen via the right
carotid. Rats were allowed to recover from surgery for one week,
after which baseline pressures were obtained for three days.
Following tail-vein injection, recordings were made. The blood
pressure recordings among groups were compared before and
after exposure to LeTx and EdTx. Rats were administered 0.5 ml
bolus of vehicle (PBS, control), LeTx (0.03 mg PA+0.015 mg LF)
or EdTx (0.15 mg PA+0.075 mg EF) by tail-vein injection.
Telemetric blood pressure and heart rate were recorded up to
72 hr.
Echocardiography Measurements
Echocardiography was used to determine effects of LeTx and
EdTx on cardiac function. At 12–24 hr prior to toxin adminis-
tration, rats were subjected to echocardiography to establish
baselines and exclude any animals with abnormal cardiac
function. We used a previously established echocardiography
protocol [35] to determine systolic and diastolic function in the
rats. Briefly, prior to echocardiography, rats were anesthetized by
administering an intramuscular injection of xylazine (10 mg/mL)-
ketamine (100 mg/mL) cocktail in 0.1 ml. Heart rates were
recorded at the beginning of echocardiography from the ECG
monitor. Echocardiographic monitoring was performed using
a General Electric Vivid I (Fairfield, CT). Transthoracic
echocardiographic parameters were measured and calculations
performed according to the American Society of Echocardiogra-
phy guidelines [36]. All measurements were performed online
using optimal digital images selected by the sonographer from
more than 10 cardiac cycles. Left ventricular (LV) end-systolic and
end-diastolic areas were traced in single-plane apical 4-chamber
view and online Simpson’s rule ejection fraction was calculated
using the modified single-plane method. Standard formulae were
used for echocardiographic calculations [37]. Rats randomized
into control, LeTx, and EdTx treatment groups. For experiments,
conscious rats were administered 0.5 ml bolus of vehicle (PBS,
control), LeTx (0.03 mg PA+0.015 mg LF) or EdTx (0.15 mg
PA+0.075 mg EF) by tail-vein injection. Each group had
echocardiography performed at one, two, three and twenty-four
hr post-injection.
Statistical Analysis
Data were averaged and shown as means6standard error of mean
(S.E.). Two sample differences were analyzed using Student’s
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unpaired t test. All calculated P values were two tailed, and a value
of P,0.05 was considered to indicate statistical significance. For
rats that died overnight, statistical analysis was based on the last
observed post-infusion time point.
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